TIDMEVG

RNS Number : 7057V

Evgen Pharma PLC

04 December 2019

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Notice of results

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it will issue its unaudited interim results for the six months ended 30 September 2019 on Tuesday, 17 December 2019.

Enquiries:

 
 Evgen Pharma plc www.evgen.com                                         via Walbrook 
 Dr Stephen Franklin, CEO 
 Richard Moulson, CFO 
 
 finnCap www.finncap.com                                        +44 (0) 20 7220 0500 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane, Manasa Patil (ECM) 
 
 WG Partners LLP                                                +44 (0) 20 3705 9330 
 Nigel Barnes / Claes Spång 
 
 Walbrook PR                            +44 (0)20 7933 87870 or evgen@walbrookpr.com 
                                                   +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                  741 001

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORFSWFILFUSESE

(END) Dow Jones Newswires

December 04, 2019 10:11 ET (15:11 GMT)

Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Evgen Pharma Charts.
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Evgen Pharma Charts.